0.95Open0.95Pre Close0 Volume19 Open Interest200.00Strike Price0.00Turnover70.52%IV21.33%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type-0.0539Delta0.0028Gamma266.33Leverage Ratio-0.1180Theta-0.0064Rho-14.36Eff Leverage0.0609Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet